Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients

This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1‐OH‐midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n = 20) and one year after weight loss surgery (n = 18), thereby providing insight into the influe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CPT Pharmacometrics Syst Pharmacol
Egile Nagusiak: Brill, MJE, Välitalo, PAJ, Darwich, AS, van Ramshorst, B, van Dongen, HPA, Rostami–Hodjegan, A, Danhof, M, Knibbe, CAJ
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728292/
https://ncbi.nlm.nih.gov/pubmed/26844012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12048
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak